Release Date: February 28, 2017
Expiration Date: February 28, 2018
Media: Internet - based
Community Practice Connections™: 11th Annual New York Lung Cancer Symposium® features a case-based discussion of current and developing therapies in lung cancer treatment, including inhibition of ALK and EGFR, immunotherapy, and chemotherapy for patients with non–small cell lung cancers (NSCLCs). Interactive clinical vignettes are followed by short video interviews with leading lung cancer experts and short summaries of clinical data related to these issues. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting by physicians engaged in the care of patients with NSCLCs.
CME/CE Activity Table of Contents
- Module 1: ALK-rearranged NSCLC
- Module 2: EGFR Mutation-positive NSCLC
- Module 3: Advanced, Squamous NSCLC
- Module 4: Metastatic Lung Adenocarcinoma Without Targetable Oncogenic Drivers
Requirements for Successful Completion
This educational activity is directed toward medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists involved in the treatment and management of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of lung cancer may also participate.
At the conclusion of this activity, you should be better prepared to:
- Assess methods by which prognostic and predictive tumor characteristics can be identified in advanced forms of lung cancer
- Use tumor and patient characteristics to optimize personalized treatment sequencing for patients with advanced non–small cell lung cancer (NSCLC)
- Discuss current and emerging roles for single agent and combination immunotherapeutic strategies in the management of advanced lung cancers
- Apply personalized approaches to manage EGFR-mutated advanced NSCLC by assessment of mutation subtypes in multiple lines of care
- Assess evolving data sets concerning the use of ALK inhibition in front-line and subsequent lines of care in advanced NSCLC
- Explain clinical trial evidence and their application concerning VEGF axis targeting in advanced NSCLC
- Explain the role of chemotherapeutic strategies as a method to personalize care in patients with lung cancer
- Integrate personalized approaches to manage challenging cases in advanced lung cancer settings
Faculty, Staff, and Planners' Disclosures
FacultyRoy S. Herbst, MD, PhD
Ensign Professor of Medicine (Medical Oncology)
Professor of Pharmacology
Chief of Medical Oncology
Associate Director for Translational Research
Yale Cancer Center
Smilow Cancer Hospital
New Haven, CT
Disclosure: Grant/Research Support: Genentech, Merck; Consultant: AstraZeneca, Eli Lilly, Genentech/Roche, Merck,Pfizer; Scientific Advisory Boards: Kolltan.
Mark G. Kris, MD
Attending, Thoracic Oncology Service
William and Joy Ruane Chair in Thoracic Oncology
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosure: Grant/Research Support: PUMA, Pfizer, Genentech; Consultant: AstraZeneca, Ariad, Roche/Genentech, Array.
Roman Perez-Soler, MD
Chairman, Department of Oncology
Montefiore Medical Center
Professor of Medicine and Molecular Pharmacology
Albert Einstein College of Medicine
Deputy Director, Albert Einstein Cancer Center
Disclosure: Grant/Research Support: National Cancer Institute; Consultant: AstraZeneca, Clovis, Roche/Genentech, Boehringer Ingelheim, Lilly, Adgero; Stock/Shareholder: Adgero.
H. Jack West, MD
Medical Director, Thoracic Oncology Program
Swedish Cancer Institute
Founder & President, GRACE (cancerGRACE.org)
Disclosure: Consultant: Ariad, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Genentech/Roche, Guardant Health, Merck, Novartis, Trovagene; Speaker’s Bureau: Ariad, Genentech/Roche, Lilly.
Disclosure Policy and Resolution of Conflicts of Interest (COI)
It is the policy of PER® to ensure the fair balance, independence, objectivity, and scientific objectivity in all our CME activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
Staff and Planners’ Disclosures
The staff of PER® have no relevant financial relationships with commercial interests to disclose.
Off-Label Disclosure and Disclaimer
This CME/CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient's medical condition.
The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of Physicians’ Education Resource®, LLC, or any of the companies that provided commercial support for this activity.
CME Provider Contact Information
Physicians’ Education Resource®, LLC
2 Clarke Drive
Cranbury, NJ 08512
Hardware And Software Requirements
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)
Minimum System Requirements (Windows)
- A Pentium-based PC or compatible computer
- At least 64MB of RAM
- Windows 95/98/NT/ME/2000/XP/Vista system software
- Screen resolution of 1024 x 786 or larger recommended
- PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise
Minimum System Requirements (Mac OS)